On the stock market since 2024, it operates in the world of health and science. It has 76 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
There is $176.5M in the vault; even if every debt were paid off, $172.1M would remain.
Over the last 12 months, company executives reported 37 buys and 18 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $34.60 — 55% above today’s price.
A loss of $63.2M against $0 in annual sales.
This stock swings about 2.6 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, ANRO sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ANRO is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (49/100) says the stock isn’t cheap.